Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Pathology & Oncology Research
Published in: Pathology & Oncology Research 2/2011

01-06-2011 | Research

PHOSPHO-STAT5 Expression is Associated with Poor Prognosis of Human Colonic Adenocarcinoma

Authors: Yin-Ling Mao, Zhi-Wei Li, Chang-Jie Lou, Da Pang, Yan-Qiao Zhang

Published in: Pathology & Oncology Research | Issue 2/2011

Login to get access

Abstract

The signal transducer and activator of transcription-5 (STAT5) protein has been shown to play an important role in tumor progression through stimulating cell proliferation and preventing apoptosis. STAT5 activation has been observed in a variety of human tumors and cancer cell lines. However, it is not clear how activated STAT5 is expressed in colon cancer. In this study, we aimed to investigate phospho-STAT5 (activated form of STAT5) expression and its relationship with the clinicopathological factors and overall survival of patients with colonic adenocarcinoma. A total of 121 histological samples were selected for this study. Immunohistochemistry was used to detect the expression of phospho-STAT5. Analysis of the immunohistochemical staining was based on the proportion of stained cells in the field: positive, >15% stained cells, and negative, <15% stained cells. Survival times were analyzed using the Kaplan-Meier method, and the differences between groups were assessed with the log-rank test. A multivariate Cox regression model was used for prognostic power analysis. Expression of phospho-STAT5 was observed in the cytoplasms of colonic adenocarcinoma cells. Univariate analysis showed that phospho-STAT5 immunoreactivity was correlated with the depth of tumor invasion (P-value = 0.009), tumor-node-metastasis (TNM) stage (P-value = 0.048) and shorter overall survival times (P-value = 0.026). Lymph node metastasis, distant metastasis and TNM stage were associated with shorter overall survival times (P-value range from 0.003- < 0.001). Multivariate analysis showed that only distant metastasis was an independent predictor of overall survival time (P-value = 0.016). Our findings first demonstrate that phospho-STAT5 is frequently present and active in colonic adenocarcinoma and related to poor prognosis.
Literature
1.
Lievre A, Bachet JB, Le Corre D et al (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66:3992–3995PubMedCrossRef
2.
Galizia G, Lieto E, Ferraraccio F et al (2004) Determination of molecular marker expression can predict clinical outcome in colon carcinomas. Clin Cancer Res 10:3490–3499PubMedCrossRef
3.
Muto T, Kotake K, Koyama Y (2001) Colorectal cancer statistics in Japan: data from JSCCR registration, 1974–1993. Int J Clin Oncol 6:171–176PubMedCrossRef
4.
Newland RC, Dent OF, Lyttle MN et al (1994) Pathologic determinants of survival associated with colorectal cancer with lymph node metastases. A multivariate analysis of 579 patients. Cancer 73:2076–2082PubMedCrossRef
5.
Guba M, Seeliger H, Kleespies A et al (2004) Vascular endothelial growth factor in colorectal cancer. Int J Colorectal Dis 19:510–517PubMedCrossRef
6.
Kusaba T, Nakayama T, Yamazumi K et al (2006) Activation of STAT3 is a marker of poor prognosis in human colorectal cancer. Oncol Rep 15:1445–1451PubMed
7.
Buettner R, Mora LB, Jove R (2002) Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 8:945–954PubMed
8.
Calo V, Migliavacca M, Bazan V et al (2003) STAT proteins: from normal control of cellular events to tumorigenesis. J Cell Physiol 197:157–168PubMedCrossRef
9.
10.
Ramana CV, Chatterjee-Kishore M, Nguyen H et al (2000) Complex roles of Stat1 in regulating gene expression. Oncogene 19:2619–2627PubMedCrossRef
11.
Corvinus FM, Orth C, Moriggl R et al (2005) Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia 7:545–555PubMedCrossRef
12.
Gong W, Wang L, Yao JC et al (2005) Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of human gastric cancer. Clin Cancer Res 11:1386–1393PubMedCrossRef
13.
Wei D, Le X, Zheng L et al (2003) Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene 22:319–329PubMedCrossRef
14.
Coffer PJ, Koenderman L, de Groot RP (2000) The role of STATs in myeloid differentiation and leukemia. Oncogene 19:2511–2522PubMedCrossRef
15.
Li H, Zhang Y, Glass A et al (2005) Activation of signal transducer and activator of transcription-5 in prostate cancer predicts early recurrence. Clin Cancer Res 11:5863–5868PubMedCrossRef
16.
Li H, Ahonen TJ, Alanen K et al (2004) Activation of signal transducer and activator of transcription 5 in human prostate cancer is associated with high histological grade. Cancer Res 64:4774–4782PubMedCrossRef
17.
Nevalainen MT, Xie J, Torhorst J et al (2004) Signal transducer and activator of transcription-5 activation and breast cancer prognosis. J Clin Oncol 22:2053–2060PubMedCrossRef
18.
Lee TK, Man K, Poon RT et al (2006) Signal transducers and activators of transcription 5b activation enhances hepatocellular carcinoma aggressiveness through induction of epithelial-mesenchymal transition. Cancer Res 66:9948–9956PubMedCrossRef
19.
Xiong H, Su WY, Liang QC et al (2009) Inhibition of STAT5 induces G1 cell cycle arrest and reduces tumor cell invasion in human colorectal cancer cells. Lab Invest 89:717–725PubMedCrossRef
20.
O’Connell JB, Maggard MA, Ko CY (2004) Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 96:1420–1425PubMedCrossRef
21.
Jass JR, Sobin LH, Watanabe H (1990) The World Health Organization’s histologic classification of gastrointestinal tumors. A commentary on the second edition. Cancer 66:2162–2167PubMedCrossRef
22.
Hsiao JR, Jin YT, Tsai ST et al (2003) Constitutive activation of STAT3 and STAT5 is present in the majority of nasopharyngeal carcinoma and correlates with better prognosis. Br J Cancer 89:344–349PubMedCrossRef
23.
Ahonen TJ, Xie J, LeBaron MJ et al (2003) Inhibition of transcription factor Stat5 induces cell death of human prostate cancer cells. J Biol Chem 278:27287–27292PubMedCrossRef
24.
Ren S, Cai HR, Li M et al (2002) Loss of Stat5a delays mammary cancer progression in a mouse model. Oncogene 21:4335–4339PubMedCrossRef
25.
Cotarla I, Ren S, Zhang Y et al (2004) Stat5a is tyrosine phosphorylated and nuclear localized in a high proportion of human breast cancers. Int J Cancer 108:665–671PubMedCrossRef
26.
Harir N, Boudot C, Friedbichler K et al (2008) Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade. Blood 112:2463–2473PubMedCrossRef
27.
Harir N, Pecquet C, Kerenyi M et al (2007) Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias. Blood 109:1678–1686PubMedCrossRef
28.
Klampfer L (2008) The role of signal transducers and activators of transcription in colon cancer. Front Biosci 13:2888–2899PubMedCrossRef
Metadata
Title
PHOSPHO-STAT5 Expression is Associated with Poor Prognosis of Human Colonic Adenocarcinoma
Authors
Yin-Ling Mao
Zhi-Wei Li
Chang-Jie Lou
Da Pang
Yan-Qiao Zhang
Publication date
01-06-2011
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 2/2011
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-010-9321-3

Other articles of this Issue 2/2011

Pathology & Oncology Research 2/2011 Go to the issue

Research

Combined Antitumor Effect of Ad-bFGF-siRNA and Ad-Vpr on the Growth of Xenograft Glioma in Nude Mouse Model

Research

Open MR-Guided High-Dose-Rate (HDR) Prostate Brachytherapy: Feasibility and Initial Experiences Open MR-Guided High-Dose-Rate (HDR) Prostate Brachytherapy

Short Communication

Application of Linear Discriminant Analysis and Attenuated Total Reflectance Fourier Transform Infrared Microspectroscopy for Diagnosis of Colon Cancer

Research

The Role of Viral Infections in the Development of Dilated Cardiomyopathy

Case Report

Intestinal Langerhans Cell Histiocytosis-like Lesion in an Adult Presented with Diverticulitis: A Reactive or Neoplastic Condition?

Research

Are GSTM1, GSTT1 and CAG Repeat Length of Androgen Receptor Gene Polymorphisms Associated with Risk of Prostate Cancer in Iranian Patients?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits